“Milestone” drug trial for hard-to-treat UC

An experimental drug has been successfully trialed in a population of ulcerative colitis patients with particularly refractory disease.

Etrolizumab – a humanised monoclonal antibody targeting the integrin subunit beta-7 – was given subcutaneously at two different doses and compared to placebo in 124 patients from 11 countries, including Australia.

Twenty-one percent of patients given etrolizumab 100mg achieved endoscopic remission at ten weeks, compared with none of the patients taking placebo,